KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis.

Sebastiano Buti, Melissa Bersanelli, Giulia Mazzaschi, Carlo Cattrini, Matteo Brunelli, Massimo Di Maio

Immunotherapy 14(2) 145-153

PMID34806404
PMCID-
DOI10.2217/imt-2021-0157
发表日期2021-11-22
摘要

摘要

Background: Combinations based on immune checkpoint inhibitors are the new first-line standard treatment for metastatic renal cell carcinoma. Sarcomatoid renal cell carcinoma (sRCC) has a dismal prognosis but good immunogenicity. Methods: The authors performed a network meta-analysis of Phase III randomized trials of immune checkpoint inhibitor-based combinations versus standard tyrosine kinase inhibitor monotherapy reporting data for sRCC. The end points were overall survival, progression-free survival and objective response rate. Results: Five trials comprising 569 sRCC patients (out of a total of 4409 metastatic renal cell carcinoma patients) were included. Nivolumab-cabozantinib was the highest ranking treatment for overall survival (p-score = 88%) and progression-free survival (p-score = 81%). Atezolizumab-bevacizumab had the highest rank for objective response rate (p-score = 80%). Conclusion: Despite some limitations, nivolumab-cabozantinib might be the preferred first-line option for sRCC in terms of efficacy.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。